Bispecific antibodies are next new thing in cancer immunotherapy – STAT

Posted by on February 27, 2019 1:02 pm
Tags:
Categories: Crispr Articles

Source: Bispecific antibodies are next new thing in cancer immunotherapy – STAT

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

| Learn More

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What’s included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Sharon Begley

Senior Writer, Science and Discovery

Sharon covers science and discovery.

Published at Wed, 27 Feb 2019 09:32:34 +0000

< Immunotherapy Today home